Circulation Population Health And Outcomes 2016, 9: 785-787
Some people can have it very early at age two, she says
The official label lists common adverse reactions such as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, bloating, belching, and reflux
Future evidence may highlight specific populations, not yet covered by guidance, who may benefit from taking them. For food and beverage, this will create challenges as well as opportunities but staying across the science is essential for exploiting them
LEAN (Liraglutide Efficacy and Action in Nonalcoholic Steatohepatitis), 14 a phase 2 study in 52 patients with biopsy-confirmed MASH, was the first to show the efficacy of a GLP-1 receptor agonist in treating MASH